Core Viewpoint - AngioDynamics, Inc. is expected to report a quarterly loss of 10 cents per share for Q2 FY26, which is a decline from a loss of 4 cents per share in the same quarter last year, while revenue is projected to increase to $76.43 million from $72.84 million year-over-year [1] Group 1: Earnings Expectations - The company will release its Q2 earnings results on January 6, 2026, before the market opens [1] - Analysts anticipate a quarterly loss of 10 cents per share, compared to a loss of 4 cents per share in the previous year [1] - The consensus estimate for quarterly revenue is $76.43 million, up from $72.84 million a year earlier [1] Group 2: Stock Performance - AngioDynamics shares fell by 1.8% to close at $12.87 on the previous Friday [2] Group 3: Analyst Ratings - Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on October 3, 2025 [3] - HC Wainwright & Co. analyst Yi Chen also maintained a Buy rating with a price target of $16 on July 16, 2025 [3] - The accuracy rates for these analysts are 62% and 66%, respectively [3]

AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for its second quarter before the opening bell on Tuesday, Jan. 6, 2026.Analysts expect the Latham, New York-based company to report a quarterly loss at 10 cents per share, versus a year-ago loss of 4 cents per share. The consensus estimate for AngioDynamics quarterly revenue is $76.43 million, compared to $72.84 million a year earlier, according to data from Benzinga Pro.On Oct. 2, AngioDynamics raised its FY26 adjusted EPS guidance.AngioDynam ...

KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 2:15 p.m. Pacific Time. Interested parties may access the live webcast and replay of the presentation by visiting the Kestra Medical Technologies investor relations website. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable ...

Core Insights - PathoCare Holdings has received a private third-party tender offer for the secondary purchase of shares, indicating an implied company valuation of approximately $1.75 billion [1] - The company previously underwent a $150 million venture investment, recapitalization, and a secondary tender offer at a $500 million valuation [1][5] - An independent financial advisory firm has been appointed to conduct a formal fairness opinion and updated valuation review following the latest tender offer [2] Financial Activities - The earlier $500 million valuation was assigned by Lehrer Financial, a financial consulting firm [2] - PathoCare Holdings has increased the size of its planned private equity financing round from up to $25 million to up to $50 million due to heightened institutional interest and market demand [3] Use of Proceeds - The company plans to utilize the proceeds from the proposed financing to accelerate product development, expand intellectual property, enhance regulatory readiness, and commercialize its flagship diagnostic platform, including the PathoWand point-of-care system [4] Management Commentary - PathoCare Holdings' chairman, Mychal Jefferson, stated that the significant third-party tender offer reflects growing institutional confidence in the long-term potential of the diagnostic platform [4] - The Board is committed to proceeding with discipline and transparency by commissioning an independent fairness opinion before making final decisions [5]

Asia has become the world’s fastest growing healthcare market, projected to reach US$5 trillion by 2030.The boom is underpinned by the region’s aging populations, complemented by expansion of the middle-class.As healthcare demand rises, healthcare providers, health-tech innovators and health-related infrastructure across Asia are poised to benefit.Here are three resilient companies that are tapping into Asia’s healthcare boom.Raffles Medical Group (SGX: BSL)Raffles Medical Group (RMG) is a Singapore-based i ...

High valuations don’t necessarily preclude further market-beating gains, but they do tend to drive more volatility, and I think Edwards Lifesciences ( EW ) is a case in point. While this company continues to log impressive growth for its size, the Street stillAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am ...

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which concealed significant operational failures that ultimately led to a drastic cut in guidance and a stock price crash [3][5]. - Key undisclosed operational issues include: - Medicare claims software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device impacted demand for the new Inspire V, leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026, to discuss their legal rights [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [5].

Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The ...